Fc-optimized checkpoint antibodies for cancer immunotherapy.

IF 12.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Trends in molecular medicine Pub Date : 2024-11-01 DOI:10.1016/j.molmed.2024.10.008

Rony Dahan, Alan J Korman

引用次数: 0

Abstract

The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.

查看原文本刊更多论文

用于癌症免疫疗法的 Fc 优化检查点抗体。

用于癌症治疗的检查点抗体的开发一直遵循阻断 T 细胞抑制信号的原则。人们认识到 Fc 结构域通过消耗免疫抑制群体和激活髓系细胞在治疗活动中的作用，这促使人们转向开发优化的 Fc 工程检查点抗体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in molecular medicine 医学-生化与分子生物学

CiteScore

24.60

自引率

0.00%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Trends in Molecular Medicine (TMM) aims to offer concise and contextualized perspectives on the latest research advancing biomedical science toward better diagnosis, treatment, and prevention of human diseases. It focuses on research at the intersection of basic biology and clinical research, covering new concepts in human biology and pathology with clear implications for diagnostics and therapy. TMM reviews bridge the gap between bench and bedside, discussing research from preclinical studies to patient-enrolled trials. The major themes include disease mechanisms, tools and technologies, diagnostics, and therapeutics, with a preference for articles relevant to multiple themes. TMM serves as a platform for discussion, pushing traditional boundaries and fostering collaboration between scientists and clinicians. The journal seeks to publish provocative and authoritative articles that are also accessible to a broad audience, inspiring new directions in molecular medicine to enhance human health.